Company news

Verrica Pharmaceuticals Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Verrica Announces Pricing of $42.0 Million Public Offering

November 20, 2024

Verrica Announces Proposed Public Offering

November 19, 2024

Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition

November 3, 2024

Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference

October 23, 2024

Verrica Pharmaceuticals Announces Restructuring of Commercial Organization

October 1, 2024

Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results

August 13, 2024

Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma

August 13, 2024

Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.

June 30, 2024

Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts

May 14, 2024

Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results

May 12, 2024

Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference

April 1, 2024

Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA

March 25, 2024

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results

February 28, 2024

Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024

February 21, 2024

Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH™ from Centers for Medicare and Medicaid Services

January 28, 2024

Verrica Pharmaceuticals Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma

January 4, 2024

Verrica Pharmaceuticals Announces Receipt of Minutes from Type C Meeting with FDA Regarding Clinical Development of YCANTH™ for the Treatment of Common Warts

January 3, 2024

Verrica Pharmaceuticals Announces Specialty Pharmacy Partnership Agreement with Walgreens to Distribute YCANTH™

January 2, 2024

Verrica Pharmaceuticals Announces Presentation at the Jefferies Global Healthcare Conference in London

November 9, 2023

Verrica Pharmaceuticals Reports Third Quarter 2023 Financial Results

November 8, 2023

Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference

August 30, 2023

Verrica Pharmaceuticals Announces First Sale of YCANTH™ to FFF Enterprises

August 23, 2023

Verrica Pharmaceuticals Announces Presentation of Lesion Clearance Data from an Ongoing Phase 2 Study of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology (AAD) 2023 Innovation Academy Meeting

August 9, 2023

Verrica Pharmaceuticals Reports Second Quarter 2023 Financial Results

August 7, 2023

Verrica Pharmaceuticals Announces Acceptance of Abstract Featuring Clinical Data of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology Association’s (AAD) 2023 Innovation Academy Meeting

August 2, 2023

Verrica Pharmaceuticals Announces Closing of $125 Million Debt Financing with OrbiMed

July 25, 2023

Following FDA Approval of YCANTH™ for the Treatment of Molluscum Contagiosum, Verrica Pharmaceuticals Enters into Non-Binding Term Sheet for up to $125 Million Debt Financing; Company to Host Conference Call and Webcast This Morning at 8: 30 am ET

July 23, 2023

Verrica Pharmaceuticals Announces FDA Approval of YCANTH™ (cantharidin) topical solution as the First FDA approved Treatment of Pediatric and Adult Patients with Molluscum Contagiosum

July 20, 2023

Verrica Pharmaceuticals Announces Presentation at the Jefferies Healthcare Conference in New York

May 30, 2023

Verrica Pharmaceuticals Announces Presentation at the RBC Capital Markets Global Healthcare Conference

May 9, 2023

Verrica Pharmaceuticals Reports First Quarter 2023 Financial Results

May 8, 2023

Verrica Pharmaceuticals Announces Dosing of the First Patient in Part 2 of Phase 2 Study Evaluating VP-315 for the Treatment of Basal Cell Carcinoma

April 11, 2023

Verrica Pharmaceuticals Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference

April 10, 2023

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results

March 5, 2023

Verrica Pharmaceuticals Announces Participation at The Cowen 43rd Annual Health Care Conference

February 27, 2023

Verrica Pharmaceuticals Announces FDA Acceptance of Filing of Resubmitted NDA for VP-102 for the Treatment of Molluscum Contagiosum

February 26, 2023

Verrica Announces Pricing of $32.5 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

February 20, 2023

Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum

January 23, 2023

Verrica Pharmaceuticals Announces the Successful Technology Transfer of Bulk Solution Manufacturing of VP-102 to Piramal Pharma Solutions

January 3, 2023

Verrica Pharmaceuticals Reports Third Quarter 2022 Financial Results

November 6, 2022

Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 24th Annual Global Investment Conference

August 30, 2022

Verrica Pharmaceuticals Reports Second Quarter 2022 Financial Results

August 10, 2022

Verrica Pharmaceuticals Announces Start of Phase 3 Trial of VP-102 for the Treatment of Molluscum Contagiosum by Torii Pharmaceutical Co., Ltd. in Japan

July 31, 2022

Verrica Announces Proposed Public Offering of Common Stock

June 28, 2022

Verrica Announces Pricing of Public Offering of Common Stock

June 28, 2022

Verrica Pharmaceuticals Holds Type A Meeting with FDA for VP-102 for Molluscum Contagiosum

June 27, 2022

Verrica Receives Complete Response Letter from the FDA for its NDA for VP-102 as a Direct Result of Deficiencies at General Reinspection of Sterling Pharmaceuticals Services, LLC

May 23, 2022

Verrica Pharmaceuticals Reports First Quarter 2022 Financial Results

May 8, 2022

Verrica Pharmaceuticals Announces Participation in the 21st Annual Needham Virtual Healthcare Conference

April 6, 2022

Verrica Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of LTX-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma

April 4, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 11 calls. Every call is listed under its year.

Decks

The 5 newest of 24 decks. Every deck is listed under its year.